Autopsy report · NCT00864513

Study of Pemetrexed for Second-Line Pancreas Cancer

“At interim analysis the study did not meet the response criteria to continue”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 5 months after it had already started.
• Ran for about 1 year 9 months before it stopped.
• 17 participants enrolled.
• Results were posted on the registry 6 years 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Georgetown University

Sponsor type

University, hospital or other

Conditions

Pancreas Cancer

Interventions

pemetrexed

Participants

17

Sites

1

Countries

United States

Trials that died the same way

• Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer
  “Interim analysis determined the study did not meet criteria to proceed” (94% match in meaning)
• Adherence to Antidepressant Treatment in Subjects With Depression
  “The study was terminated early based on the planned interim analysis that did not meet criteria for continuation.” (85% match in meaning)
• A Comparison of Surgical Preparations and Wound Infection Rates for Elective Cesarean Sections
  “Study was stopped following interim analysis.” (83% match in meaning)
• Study Evaluating PPM-204 In Subjects With Type 2 Diabetes
  “Study terminated as a result of interim analysis not meeting predetermined criteria.” (83% match in meaning)
• Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke
  “The interim analysis of another associated study is not very effective” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.